Brief: FDA Approves Brinsupri As First Treatment For Non-Cystic Fibrosis Bronchiectasis
12/08/2025 18:32
Aug 12 (Reuters) - Insmed Inc INSM.O: FDA APPROVES BRINSUPRI™ (BRENSOCATIB) AS THE FIRST AND ONLY TREATMENT FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS, A SERIOUS, CHRONIC LUNG DISEASE INSMED INC - BRINSUPRI 10 MG AND 25 MG DOSES APPROVED FOR NCFB INSMED INC - PLANS TO FILE APPLICATIONS FOR BRENSOCATIB IN JAPAN IN 2025 Source text: ID:nPn34v3m3a Further company coverage: INSM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector